CovidChloroV1, Main, Exploration, bibRecordById, pubmed:32750131

Drug interactions: a review of the unseen danger of experimental COVID-19 therapies.

Identifieur interne : 001399 ( Main/Exploration ); précédent : 001398; suivant : 001400

Drug interactions: a review of the unseen danger of experimental COVID-19 therapies.

Auteurs : Catherine Hodge [Royaume-Uni] ; Fiona Marra [Royaume-Uni] ; Catia Marzolini [Royaume-Uni, Suisse] ; Alison Boyle [Royaume-Uni] ; Sara Gibbons [Royaume-Uni] ; Marco Siccardi [Royaume-Uni] ; David Burger [Pays-Bas] ; David Back [Royaume-Uni] ; Saye Khoo [Royaume-Uni]

Source :

The Journal of antimicrobial chemotherapy [ 1460-2091 ] ; 2020.

RBID : pubmed:32750131

Descripteurs français

KwdFr :
- Antiviraux (effets indésirables), Antiviraux (pharmacocinétique), Antiviraux (usage thérapeutique), Betacoronavirus (MeSH), Humains (MeSH), Infections à coronavirus (traitement médicamenteux), Interactions médicamenteuses (MeSH), Pandémies (MeSH), Pneumopathie virale (traitement médicamenteux), Traitements en cours d'évaluation (effets indésirables).
MESH :
- effets indésirables : Antiviraux, Traitements en cours d'évaluation.
- pharmacocinétique : Antiviraux.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : Antiviraux.
- Betacoronavirus, Humains, Interactions médicamenteuses, Pandémies.

English descriptors

KwdEn :
- Antiviral Agents (adverse effects), Antiviral Agents (pharmacokinetics), Antiviral Agents (therapeutic use), Betacoronavirus (MeSH), COVID-19 (MeSH), Coronavirus Infections (drug therapy), Drug Interactions (MeSH), Humans (MeSH), Pandemics (MeSH), Pneumonia, Viral (drug therapy), SARS-CoV-2 (MeSH), Therapies, Investigational (adverse effects).
MESH :
- chemical , adverse effects : Antiviral Agents.
- chemical , pharmacokinetics : Antiviral Agents.
- chemical , therapeutic use : Antiviral Agents.
- adverse effects : Therapies, Investigational.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- Betacoronavirus, COVID-19, Drug Interactions, Humans, Pandemics, SARS-CoV-2.

Abstract

As global health services respond to the coronavirus pandemic, many prescribers are turning to experimental drugs. This review aims to assess the risk of drug-drug interactions in the severely ill COVID-19 patient. Experimental therapies were identified by searching ClinicalTrials.gov for 'COVID-19', '2019-nCoV', '2019 novel coronavirus' and 'SARS-CoV-2'. The last search was performed on 30 June 2020. Herbal medicines, blood-derived products and in vitro studies were excluded. We identified comorbidities by searching PubMed for the MeSH terms 'COVID-19', 'Comorbidity' and 'Epidemiological Factors'. Potential drug-drug interactions were evaluated according to known pharmacokinetics, overlapping toxicities and QT risk. Drug-drug interactions were graded GREEN and YELLOW: no clinically significant interaction; AMBER: caution; RED: serious risk. A total of 2378 records were retrieved from ClinicalTrials.gov, which yielded 249 drugs that met inclusion criteria. Thirteen primary compounds were screened against 512 comedications. A full database of these interactions is available at www.covid19-druginteractions.org. Experimental therapies for COVID-19 present a risk of drug-drug interactions, with lopinavir/ritonavir (10% RED, 41% AMBER; mainly a perpetrator of pharmacokinetic interactions but also risk of QT prolongation particularly when given with concomitant drugs that can prolong QT), chloroquine and hydroxychloroquine (both 7% RED and 27% AMBER, victims of some interactions due to metabolic profile but also perpetrators of QT prolongation) posing the greatest risk. With management, these risks can be mitigated. We have published a drug-drug interaction resource to facilitate medication review for the critically ill patient.

DOI: 10.1093/jac/dkaa340
PubMed: 32750131
PubMed Central: PMC7454591

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000F91
to stream Main, to step Curation: 000F91

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Drug interactions: a review of the unseen danger of experimental COVID-19 therapies.</title>
<author><name sortKey="Hodge, Catherine" sort="Hodge, Catherine" uniqKey="Hodge C" first="Catherine" last="Hodge">Catherine Hodge</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool</wicri:regionArea>
<wicri:noRegion>Liverpool</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Marra, Fiona" sort="Marra, Fiona" uniqKey="Marra F" first="Fiona" last="Marra">Fiona Marra</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool</wicri:regionArea>
<wicri:noRegion>Liverpool</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacy, NHS Greater Glasgow and Clyde, Glasgow, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Pharmacy, NHS Greater Glasgow and Clyde, Glasgow</wicri:regionArea>
<wicri:noRegion>Glasgow</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Marzolini, Catia" sort="Marzolini, Catia" uniqKey="Marzolini C" first="Catia" last="Marzolini">Catia Marzolini</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool</wicri:regionArea>
<wicri:noRegion>Liverpool</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Division of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and Clinical Research, University Hospital of Basel, Basel, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>Division of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and Clinical Research, University Hospital of Basel, Basel</wicri:regionArea>
<wicri:noRegion>Basel</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>University of Basel, Basel, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>University of Basel, Basel</wicri:regionArea>
<wicri:noRegion>Basel</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Boyle, Alison" sort="Boyle, Alison" uniqKey="Boyle A" first="Alison" last="Boyle">Alison Boyle</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool</wicri:regionArea>
<wicri:noRegion>Liverpool</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacy, NHS Greater Glasgow and Clyde, Glasgow, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Pharmacy, NHS Greater Glasgow and Clyde, Glasgow</wicri:regionArea>
<wicri:noRegion>Glasgow</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gibbons, Sara" sort="Gibbons, Sara" uniqKey="Gibbons S" first="Sara" last="Gibbons">Sara Gibbons</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool</wicri:regionArea>
<wicri:noRegion>Liverpool</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Siccardi, Marco" sort="Siccardi, Marco" uniqKey="Siccardi M" first="Marco" last="Siccardi">Marco Siccardi</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool</wicri:regionArea>
<wicri:noRegion>Liverpool</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Burger, David" sort="Burger, David" uniqKey="Burger D" first="David" last="Burger">David Burger</name>
<affiliation wicri:level="3"><nlm:affiliation>Radboud University Medical Centre, Nijmegen, the Netherlands.</nlm:affiliation>
<country xml:lang="fr" wicri:curation="lc">Pays-Bas</country>
<wicri:regionArea>Radboud University Medical Centre, Nijmegen</wicri:regionArea>
<placeName><settlement type="city">Nimègue</settlement>
<region type="province" nuts="2">Gueldre</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Back, David" sort="Back, David" uniqKey="Back D" first="David" last="Back">David Back</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool</wicri:regionArea>
<wicri:noRegion>Liverpool</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Khoo, Saye" sort="Khoo, Saye" uniqKey="Khoo S" first="Saye" last="Khoo">Saye Khoo</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool</wicri:regionArea>
<wicri:noRegion>Liverpool</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Royal Liverpool University Hospital, Liverpool, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Royal Liverpool University Hospital, Liverpool</wicri:regionArea>
<wicri:noRegion>Liverpool</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32750131</idno>
<idno type="pmid">32750131</idno>
<idno type="doi">10.1093/jac/dkaa340</idno>
<idno type="pmc">PMC7454591</idno>
<idno type="wicri:Area/Main/Corpus">000F91</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000F91</idno>
<idno type="wicri:Area/Main/Curation">000F91</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000F91</idno>
<idno type="wicri:Area/Main/Exploration">000F91</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Drug interactions: a review of the unseen danger of experimental COVID-19 therapies.</title>
<author><name sortKey="Hodge, Catherine" sort="Hodge, Catherine" uniqKey="Hodge C" first="Catherine" last="Hodge">Catherine Hodge</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool</wicri:regionArea>
<wicri:noRegion>Liverpool</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Marra, Fiona" sort="Marra, Fiona" uniqKey="Marra F" first="Fiona" last="Marra">Fiona Marra</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool</wicri:regionArea>
<wicri:noRegion>Liverpool</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacy, NHS Greater Glasgow and Clyde, Glasgow, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Pharmacy, NHS Greater Glasgow and Clyde, Glasgow</wicri:regionArea>
<wicri:noRegion>Glasgow</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Marzolini, Catia" sort="Marzolini, Catia" uniqKey="Marzolini C" first="Catia" last="Marzolini">Catia Marzolini</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool</wicri:regionArea>
<wicri:noRegion>Liverpool</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Division of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and Clinical Research, University Hospital of Basel, Basel, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>Division of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and Clinical Research, University Hospital of Basel, Basel</wicri:regionArea>
<wicri:noRegion>Basel</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>University of Basel, Basel, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>University of Basel, Basel</wicri:regionArea>
<wicri:noRegion>Basel</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Boyle, Alison" sort="Boyle, Alison" uniqKey="Boyle A" first="Alison" last="Boyle">Alison Boyle</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool</wicri:regionArea>
<wicri:noRegion>Liverpool</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacy, NHS Greater Glasgow and Clyde, Glasgow, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Pharmacy, NHS Greater Glasgow and Clyde, Glasgow</wicri:regionArea>
<wicri:noRegion>Glasgow</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gibbons, Sara" sort="Gibbons, Sara" uniqKey="Gibbons S" first="Sara" last="Gibbons">Sara Gibbons</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool</wicri:regionArea>
<wicri:noRegion>Liverpool</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Siccardi, Marco" sort="Siccardi, Marco" uniqKey="Siccardi M" first="Marco" last="Siccardi">Marco Siccardi</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool</wicri:regionArea>
<wicri:noRegion>Liverpool</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Burger, David" sort="Burger, David" uniqKey="Burger D" first="David" last="Burger">David Burger</name>
<affiliation wicri:level="3"><nlm:affiliation>Radboud University Medical Centre, Nijmegen, the Netherlands.</nlm:affiliation>
<country xml:lang="fr" wicri:curation="lc">Pays-Bas</country>
<wicri:regionArea>Radboud University Medical Centre, Nijmegen</wicri:regionArea>
<placeName><settlement type="city">Nimègue</settlement>
<region type="province" nuts="2">Gueldre</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Back, David" sort="Back, David" uniqKey="Back D" first="David" last="Back">David Back</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool</wicri:regionArea>
<wicri:noRegion>Liverpool</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Khoo, Saye" sort="Khoo, Saye" uniqKey="Khoo S" first="Saye" last="Khoo">Saye Khoo</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool</wicri:regionArea>
<wicri:noRegion>Liverpool</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Royal Liverpool University Hospital, Liverpool, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Royal Liverpool University Hospital, Liverpool</wicri:regionArea>
<wicri:noRegion>Liverpool</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">The Journal of antimicrobial chemotherapy</title>
<idno type="eISSN">1460-2091</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (adverse effects)</term>
<term>Antiviral Agents (pharmacokinetics)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Betacoronavirus (MeSH)</term>
<term>COVID-19 (MeSH)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Drug Interactions (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>SARS-CoV-2 (MeSH)</term>
<term>Therapies, Investigational (adverse effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Antiviraux (effets indésirables)</term>
<term>Antiviraux (pharmacocinétique)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Betacoronavirus (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Infections à coronavirus (traitement médicamenteux)</term>
<term>Interactions médicamenteuses (MeSH)</term>
<term>Pandémies (MeSH)</term>
<term>Pneumopathie virale (traitement médicamenteux)</term>
<term>Traitements en cours d'évaluation (effets indésirables)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Therapies, Investigational</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antiviraux</term>
<term>Traitements en cours d'évaluation</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacocinétique" xml:lang="fr"><term>Antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term>
<term>COVID-19</term>
<term>Drug Interactions</term>
<term>Humans</term>
<term>Pandemics</term>
<term>SARS-CoV-2</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Betacoronavirus</term>
<term>Humains</term>
<term>Interactions médicamenteuses</term>
<term>Pandémies</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">As global health services respond to the coronavirus pandemic, many prescribers are turning to experimental drugs. This review aims to assess the risk of drug-drug interactions in the severely ill COVID-19 patient. Experimental therapies were identified by searching ClinicalTrials.gov for 'COVID-19', '2019-nCoV', '2019 novel coronavirus' and 'SARS-CoV-2'. The last search was performed on 30 June 2020. Herbal medicines, blood-derived products and in vitro studies were excluded. We identified comorbidities by searching PubMed for the MeSH terms 'COVID-19', 'Comorbidity' and 'Epidemiological Factors'. Potential drug-drug interactions were evaluated according to known pharmacokinetics, overlapping toxicities and QT risk. Drug-drug interactions were graded GREEN and YELLOW: no clinically significant interaction; AMBER: caution; RED: serious risk. A total of 2378 records were retrieved from ClinicalTrials.gov, which yielded 249 drugs that met inclusion criteria. Thirteen primary compounds were screened against 512 comedications. A full database of these interactions is available at www.covid19-druginteractions.org. Experimental therapies for COVID-19 present a risk of drug-drug interactions, with lopinavir/ritonavir (10% RED, 41% AMBER; mainly a perpetrator of pharmacokinetic interactions but also risk of QT prolongation particularly when given with concomitant drugs that can prolong QT), chloroquine and hydroxychloroquine (both 7% RED and 27% AMBER, victims of some interactions due to metabolic profile but also perpetrators of QT prolongation) posing the greatest risk. With management, these risks can be mitigated. We have published a drug-drug interaction resource to facilitate medication review for the critically ill patient.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32750131</PMID>
<DateCompleted><Year>2020</Year>
<Month>11</Month>
<Day>27</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>01</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2091</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>75</Volume>
<Issue>12</Issue>
<PubDate><Year>2020</Year>
<Month>12</Month>
<Day>01</Day>
</PubDate>
</JournalIssue>
<Title>The Journal of antimicrobial chemotherapy</Title>
<ISOAbbreviation>J Antimicrob Chemother</ISOAbbreviation>
</Journal>
<ArticleTitle>Drug interactions: a review of the unseen danger of experimental COVID-19 therapies.</ArticleTitle>
<Pagination><MedlinePgn>3417-3424</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1093/jac/dkaa340</ELocationID>
<Abstract><AbstractText>As global health services respond to the coronavirus pandemic, many prescribers are turning to experimental drugs. This review aims to assess the risk of drug-drug interactions in the severely ill COVID-19 patient. Experimental therapies were identified by searching ClinicalTrials.gov for 'COVID-19', '2019-nCoV', '2019 novel coronavirus' and 'SARS-CoV-2'. The last search was performed on 30 June 2020. Herbal medicines, blood-derived products and in vitro studies were excluded. We identified comorbidities by searching PubMed for the MeSH terms 'COVID-19', 'Comorbidity' and 'Epidemiological Factors'. Potential drug-drug interactions were evaluated according to known pharmacokinetics, overlapping toxicities and QT risk. Drug-drug interactions were graded GREEN and YELLOW: no clinically significant interaction; AMBER: caution; RED: serious risk. A total of 2378 records were retrieved from ClinicalTrials.gov, which yielded 249 drugs that met inclusion criteria. Thirteen primary compounds were screened against 512 comedications. A full database of these interactions is available at www.covid19-druginteractions.org. Experimental therapies for COVID-19 present a risk of drug-drug interactions, with lopinavir/ritonavir (10% RED, 41% AMBER; mainly a perpetrator of pharmacokinetic interactions but also risk of QT prolongation particularly when given with concomitant drugs that can prolong QT), chloroquine and hydroxychloroquine (both 7% RED and 27% AMBER, victims of some interactions due to metabolic profile but also perpetrators of QT prolongation) posing the greatest risk. With management, these risks can be mitigated. We have published a drug-drug interaction resource to facilitate medication review for the critically ill patient.</AbstractText>
<CopyrightInformation>© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hodge</LastName>
<ForeName>Catherine</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Marra</LastName>
<ForeName>Fiona</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Pharmacy, NHS Greater Glasgow and Clyde, Glasgow, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Marzolini</LastName>
<ForeName>Catia</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Division of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and Clinical Research, University Hospital of Basel, Basel, Switzerland.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>University of Basel, Basel, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Boyle</LastName>
<ForeName>Alison</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Pharmacy, NHS Greater Glasgow and Clyde, Glasgow, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gibbons</LastName>
<ForeName>Sara</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Siccardi</LastName>
<ForeName>Marco</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Burger</LastName>
<ForeName>David</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Radboud University Medical Centre, Nijmegen, the Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Back</LastName>
<ForeName>David</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Khoo</LastName>
<ForeName>Saye</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Royal Liverpool University Hospital, Liverpool, UK.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>J Antimicrob Chemother</MedlineTA>
<NlmUniqueID>7513617</NlmUniqueID>
<ISSNLinking>0305-7453</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004347" MajorTopicYN="Y">Drug Interactions</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D035703" MajorTopicYN="N">Therapies, Investigational</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>8</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>11</Month>
<Day>28</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>8</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32750131</ArticleId>
<ArticleId IdType="pii">5880570</ArticleId>
<ArticleId IdType="doi">10.1093/jac/dkaa340</ArticleId>
<ArticleId IdType="pmc">PMC7454591</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Ann Pharmacother. 2002 Jan;36(1):72-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11816263</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Pharmacol Ther. 2020 Aug;108(2):242-247</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32246834</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antivir Ther. 2011;16(2):249-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21447874</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Pharmacokinet. 2018 Oct;57(10):1347-1354</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29453687</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>CMAJ. 2007 Aug 14;177(4):357-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17698824</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Basic Clin Pharmacol Toxicol. 2013 Feb;112(2):132-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22900583</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2012 Jun;56(6):2846-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22391553</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Pharmacother. 2002 Apr;36(4):621-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11918509</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 15;395(10223):507-513</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32007143</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Epidemiol. 2011 Apr;64(4):383-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21195583</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2017 Mar 23;12(3):e0173509</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28334018</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Health Syst Pharm. 2017 Jun 15;74(12):888-892</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28596225</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MMWR Morb Mortal Wkly Rep. 2020 Apr 03;69(13):382-386</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32240123</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Trials. 2020 Jul 29;21(1):688</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32727613</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Acquir Immune Defic Syndr. 2006 May;42(1):52-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16639344</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2020 Mar 19;15(3):e0230548</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32191764</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Monaldi Arch Chest Dis. 2020 Mar 30;90(1):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32231348</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br J Clin Pharmacol. 2018 Jul;84(7):1617-1619</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29663482</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Swiss Med Wkly. 2014 Jan 22;144:w13906</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24452338</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 15;395(10223):497-506</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31986264</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hepatology. 1993 Jan;17(1):65-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8423043</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J STD AIDS. 2014 Jun;25(7):532-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24352136</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2017 Oct 24;61(11):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28848011</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J STD AIDS. 2019 Jun;30(7):718-722</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30975070</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2008 Jan 1;46(1):146-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18171231</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Pharmacol Ther. 2019 Jan;105(1):219-228</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29696643</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2005 Apr 15;40(8):1173-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15791519</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Antimicrob Chemother. 2020 Oct 1;75(10):3084-3086</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32556272</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Pays-Bas</li>
<li>Royaume-Uni</li>
<li>Suisse</li>
</country>
<region><li>Gueldre</li>
</region>
<settlement><li>Nimègue</li>
</settlement>
</list>
<tree><country name="Royaume-Uni"><noRegion><name sortKey="Hodge, Catherine" sort="Hodge, Catherine" uniqKey="Hodge C" first="Catherine" last="Hodge">Catherine Hodge</name>
</noRegion>
<name sortKey="Back, David" sort="Back, David" uniqKey="Back D" first="David" last="Back">David Back</name>
<name sortKey="Boyle, Alison" sort="Boyle, Alison" uniqKey="Boyle A" first="Alison" last="Boyle">Alison Boyle</name>
<name sortKey="Boyle, Alison" sort="Boyle, Alison" uniqKey="Boyle A" first="Alison" last="Boyle">Alison Boyle</name>
<name sortKey="Gibbons, Sara" sort="Gibbons, Sara" uniqKey="Gibbons S" first="Sara" last="Gibbons">Sara Gibbons</name>
<name sortKey="Khoo, Saye" sort="Khoo, Saye" uniqKey="Khoo S" first="Saye" last="Khoo">Saye Khoo</name>
<name sortKey="Khoo, Saye" sort="Khoo, Saye" uniqKey="Khoo S" first="Saye" last="Khoo">Saye Khoo</name>
<name sortKey="Marra, Fiona" sort="Marra, Fiona" uniqKey="Marra F" first="Fiona" last="Marra">Fiona Marra</name>
<name sortKey="Marra, Fiona" sort="Marra, Fiona" uniqKey="Marra F" first="Fiona" last="Marra">Fiona Marra</name>
<name sortKey="Marzolini, Catia" sort="Marzolini, Catia" uniqKey="Marzolini C" first="Catia" last="Marzolini">Catia Marzolini</name>
<name sortKey="Siccardi, Marco" sort="Siccardi, Marco" uniqKey="Siccardi M" first="Marco" last="Siccardi">Marco Siccardi</name>
</country>
<country name="Suisse"><noRegion><name sortKey="Marzolini, Catia" sort="Marzolini, Catia" uniqKey="Marzolini C" first="Catia" last="Marzolini">Catia Marzolini</name>
</noRegion>
<name sortKey="Marzolini, Catia" sort="Marzolini, Catia" uniqKey="Marzolini C" first="Catia" last="Marzolini">Catia Marzolini</name>
</country>
<country name="Pays-Bas"><region name="Gueldre"><name sortKey="Burger, David" sort="Burger, David" uniqKey="Burger D" first="David" last="Burger">David Burger</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001399 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001399 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:32750131
   |texte=   Drug interactions: a review of the unseen danger of experimental COVID-19 therapies.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:32750131" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

Drug interactions: a review of the unseen danger of experimental COVID-19 therapies.

Drug interactions: a review of the unseen danger of experimental COVID-19 therapies.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki